Serkan Kir
Istanbul, 34450, Turkey
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 20 publications
Transcriptional landscape of skeletal muscle in cancer patients.
Journal: Trends in molecular medicine
Published: October 13, 2025
Adipocyte-specific NIK depletion enhances energy metabolism and glucose tolerance in mice.
Journal: The FEBS journal
Published: September 08, 2025
Givinostat: a histone deacetylase inhibitor for Duchenne muscular dystrophy.
Journal: Trends in pharmacological sciences
Published: February 27, 2025
EDA2R-NIK signaling in cancer cachexia.
Journal: Current opinion in supportive and palliative care
Published: May 27, 2024
Tumour-induced alterations in single-nucleus transcriptome of atrophying muscles indicate enhanced protein degradation and reduced oxidative metabolism.
Journal: Journal of cachexia, sarcopenia and muscle
Published: December 14, 2023
The role of interleukin-6 family cytokines in cancer cachexia.
Journal: The FEBS journal
Published: November 30, 2023
Ectodysplasin A2 receptor signaling in skeletal muscle pathophysiology.
Journal: Trends in molecular medicine
Published: November 30, 2023
Muscle wasting: emerging pathways and potential drug targets.
Journal: Trends in pharmacological sciences
Published: July 11, 2023
Oncostatin M signaling drives cancer-associated skeletal muscle wasting.
Journal: Cell reports. Medicine
Published: June 07, 2023
Parathyroid hormone related protein (PTHrP) in patients with pancreatic carcinoma and overt signs of disease progression and host tissue wasting.
Journal: Translational oncology
Published: November 21, 2022
EDA2R-NIK signalling promotes muscle atrophy linked to cancer cachexia.
Journal: Nature
Published: July 05, 2022
Last Updated: 09/26/2026